STOCK TITAN

Royalty Pharma plc (RPRX) SEC Filings

RPRX NASDAQ

Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.

Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.

Rhea-AI Summary

Royalty Pharma plc (RPRX) reported that SCH Investment Partners LLC sold 100,000 Class A ordinary shares on November 17, 2026, at a weighted average price of $68.1471 per share; individual sale prices ranged from $67.78 to $68.58. The sale was made under a Rule 10b5-1 plan adopted by reporting person Christopher Hite, EVP & Chairman, Partnering, on March 20, 2026. After the sale, the LLC held 177,523 shares indirectly; Hite also held 23,200 shares directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
insider
-
Rhea-AI Summary

Royalty Pharma plc’s executive vice president and chief financial officer, Terrance P. Coyne, reported indirect sales of 257,122 Class A ordinary shares through entities on November 16 and November 17, 2026. Reported weighted-average prices were $68.8680–$68.8681 per share on November 16 and $68.3047 per share on November 17. The sales were made under a Rule 10b5-1 plan adopted August 6, 2026. TPC RP EPA1 LLC reported zero shares after selling 7,122 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
insider
-
Rhea-AI Summary

Royalty Pharma plc (RPRX) EVP, Research & Investments Marshall Urist reported that Sandy Lamm LLC sold 25,000 Class A Ordinary Shares on November 16, 2026, in two transactions under a Rule 10b5-1 plan adopted August 7, 2026. The weighted-average prices were $69.4701 for 23,592 shares and $69.9941 for 1,408 shares; the disclosed transaction ranges were $68.93–$69.92 and $69.92–$70.00 per share, respectively.

The statement also lists 19,020 shares held indirectly by an IRA and 5,341 shares held directly. It says Marshall Urist and family vehicles hold limited partnership interests exchangeable into 2,294,120 Class A Ordinary Shares, and Class E Ordinary Shares exchangeable into 1,356,528 Class A Ordinary Shares; the Class E shares are subject to vesting conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
insider
Rhea-AI Summary

Royalty Pharma plc reports that SCH Investment Partners LLC plans to sell 150,000 Class A ordinary shares, with an aggregate market value of $10,176,000 and an approximate sale date of November 17, 2026. SCH Investment Partners LLC is listed with an Officer relationship to Royalty Pharma. The shares were acquired from the issuer in a private transaction on May 13, 2024. The planned sale is connected to a selling plan dated March 20, 2026, intended to comply with Rule 10b5-1(c).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
other
-
Rhea-AI Summary

Royalty Pharma plc (RPRX) officer Terrance Coyne’s Form 144 notice covers a proposed sale of 257,122 common shares, with an aggregate market value of $17,619,285.05 and an approximate sale date of November 16, 2026. The notice says the sales are made in connection with a selling plan dated August 6, 2026, intended to comply with Rule 10b5-1(c).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
other
-
Rhea-AI Summary

Royalty Pharma plc (RPRX) has a notice of a proposed sale of 150,000 Class A ordinary shares by Sandy Lamm LLC, whose relationship to the issuer is listed as officer. The approximate sale date is November 16, 2026, and the shares have an aggregate market value of $10,278,750. Merrill Lynch is named as the broker. Sandy Lamm LLC acquired the shares from the issuer in a private transaction on June 16, 2020. The sale is made in connection with a selling plan dated August 7, 2026, intended to comply with Rule 10b5-1(c).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
other
Rhea-AI Summary

Royalty Pharma plc EVP & CFO Terrance P. Coyne reported that, on November 6, 2026, TPC RP 2021, LLC and TPC RP, LLC exchanged 15,000 and 10,000 RPI US Partners 2019, LP interests, respectively, for 150,000 and 100,000 Class A Ordinary Shares; the exchange involved no additional value. Following the conversions, the entities were reported with 102,526 and 473,942 LP interests, respectively. On November 4, 2026, TPC RP EPA1 LLC acquired 7,122 Class A Ordinary Shares in settlement of Equity Performance Awards, with 7,122 shares reported following the acquisition. A separate holding lists 43,350 LP interests held through TPC ICAI, LLC, exchangeable for 433,500 Class A Ordinary Shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
insider
-
Rhea-AI Summary

Royalty Pharma plc (RPRX) reported that Marshall Urist, EVP, Research & Investments, received 5,341 Class A ordinary shares directly on November 4, 2026, in settlement of Equity Performance Awards. On November 6, 2026, 15,000 RPI US Partners 2019, LP interests held by Sandy Lamm LLC were exchanged for 150,000 Class A ordinary shares, with no additional value paid. After the exchange, Sandy Lamm LLC held 229,412 LP interests and 150,000 Class A shares. Urist also reported 19,020 Class A shares held by an IRA and Class E ordinary shares exchangeable into 1,356,528 Class A shares, subject to vesting conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
insider
-
Rhea-AI Summary

Royalty Pharma plc CEO and Chairman Pablo G. Legorreta acquired 42,209 Class A Ordinary Shares on November 4, 2026, in an exempt acquisition connected with settlement of Equity Performance Awards under Rule 16b-3. His directly held position following the acquisition was 1,350,029 Class A Ordinary Shares. Separately, Legorreta and family vehicles he controls hold 73,195,660 Class B Ordinary Shares and 13,356,742 Class E Ordinary Shares of Royalty Pharma Holdings Ltd., exchangeable into the same respective numbers of Class A Ordinary Shares; the Class E shares are subject to vesting conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
insider
Rhea-AI Summary

Royalty Pharma plc (RPRX) reports an award-related acquisition of 7,122 Class A Ordinary Shares on November 4, 2026, held indirectly through SCH Investment Partners LLC for reporting person Christopher Hite, EVP & Chairman, Partnering. The acquisition was in connection with settlement of Equity Performance Awards.

The reported post-transaction positions were 277,523 shares held indirectly and 23,200 shares held directly. Family vehicles controlled by Hite hold interests exchangeable into 866,410 Class A Ordinary Shares through RPI US Partners 2019, LP and RPH Class E Ordinary Shares exchangeable into 1,238,789 Class A Ordinary Shares; the Class E shares are subject to vesting conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
insider

FAQ

How many Royalty Pharma plc (RPRX) SEC filings are available on StockTitan?

StockTitan tracks 138 SEC filings for Royalty Pharma plc (RPRX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Royalty Pharma plc (RPRX)?

The most recent SEC filing for Royalty Pharma plc (RPRX) was filed on November 18, 2026.